CymaBay Therapeutics, Inc, A Gilead Company, is focused on improving the lives of people living with primary biliary cholangitis or PBC. Through Gilead’s leadership and long-standing commitment to innovation in liver disease, we are working to advance seladelpar, a potential best-in-disease therapy for people with PBC. Seladelpar is investigational and currently under review by the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and the U.K. Medicines Healthcare products Regulatory Agency (MHRA) for the treatment of PBC.
Products and Services Information
Working to improve the lives of people living with PBC.
Northwell Health’s Office of CME invites you to click the button below to claim and submit a raffle ticket for visiting this booth.
The more booths you visit and the more raffle tickets you submit, the greater your chances of winning. Only one submission per booth counts. Hope you win!
Please enter your name and email below to submit your virtual raffle ticket.
